Patrys Starts Manufacturing Its Injectable Delirium Drug Ahead of 2026 Trials
Patrys advances RLS-2201 toward clinical trials with manufacturing and regulatory milestones
Patrys Limited (ASX: PAB) has initiated engineering batch manufacturing and commenced US regulatory engagement for RLS-2201, its proprietary injectable Quetiapine formulation targeting delirium in acute care settings. The company remains on track for Phase 0 clinical trial initiation in H2 2026, marking critical de-risking milestones that bring the program closer to human trials.
Patrys RLS-2201 Clinical Trial Manufacturing activities are now progressing across multiple parallel workstreams, demonstrating execution capability and reducing single-point-of-failure risk for investors tracking the clinical timeline. Delirium affects between 30-70% of intensive care patients, yet no rapid-acting injectable therapy is currently approved for acute delirium treatment.
When big ASX news breaks, our subscribers know first
Engineering batch production underway at BioCina
BioCina, an Australian contract development and manufacturing organisation (CDMO) specialising in sterile injectable drug product formulation, is producing the engineering batch. This represents the first production run under conditions designed to replicate commercial-scale manufacturing processes.
The engineering batch will support three key development activities:
- Confirmation of manufacturing process reproducibility
- Generation of material for stability testing
- Production of early material for clinical trial activities
Successful completion enables manufacture of GMP clinical trial material required for Phase I dosing, a prerequisite for advancing to human studies. This milestone represents a tangible step toward converting development work into trial-ready drug product.
What is delirium and why does it need a new treatment?
Delirium is an acute brain dysfunction characterised by confusion, disorientation, and impaired cognitive function, commonly seen in ICU patients. The condition affects between 30-70% of intensive care patients, yet current treatment options are inadequate.
No approved rapid-acting injectable therapy exists for acute delirium treatment. This creates a significant gap for patients who cannot take oral medication due to their medical condition or inability to swallow. RLS-2201 addresses this unmet need by reformulating Quetiapine, an established oral drug, into an injectable form suitable for acute hospital use.
The large addressable patient population combined with no direct competition in the injectable space creates a differentiated market opportunity if RLS-2201 reaches approval.
FDA regulatory pathway and CRO selection progress
Patrys has commenced engagement with Facet Life Sciences, a specialist US regulatory affairs advisory group, ahead of FDA investigational new drug application (IND) submission. The program is expected to pursue the FDA 505(b)(2) regulatory pathway, allowing the company to leverage existing Quetiapine safety and clinical data rather than starting from scratch.
Current regulatory discussions are focused on:
- Leveraging existing safety and clinical data for oral Quetiapine
- Defining the clinical development strategy for the RLS-2201 formulation
- Confirming the planned Phase 0 clinical study design
- Preparing regulatory documentation, inclusive of ethical frameworks required for the planned Phase I trial
The company is in advanced discussions with a shortlist of specialist Contract Research Organisations (CROs) experienced in early phase clinical trials. These discussions address:
- Clinical trial site selection
- Subject recruitment strategy
- Clinical operations management
- Regulatory and ethics approval support
Patrys expects to finalise its CRO appointment in Q2 CY2026 and will update shareholders following execution of a formal agreement.
The 505(b)(2) pathway offers potential to accelerate development timelines and reduce costs compared to traditional drug development, a meaningful efficiency gain for a clinical-stage company. Early regulatory engagement is intended to ensure alignment with the FDA and incorporate agency feedback into the clinical development pathway.
Dr Samantha South, Chief Executive Officer
“With manufacturing development underway and regulatory engagement progressing, these activities represent important de-risking steps for the RLS-2201 program as we move toward entering clinical trials. By reformulating a well-known therapeutic into an injectable treatment designed for acute hospital use, we believe RLS-2201 has the potential to address a significant unmet need in the treatment of delirium.”
Key milestones and timeline ahead
The near-term catalysts investors should monitor provide visibility on program execution and potential share price inflection points.
| Milestone | Expected Timing |
|---|---|
| Engineering batch completion | In progress |
| CRO appointment finalised | Q2 CY2026 |
| Phase 0 clinical trial initiation | H2 2026 |
The next major ASX story will hit our subscribers first
RLS-2201 complements Patrys’ broader pipeline
RLS-2201 sits alongside Patrys’ core deoxymab antibody platform targeting immune-mediated inflammatory diseases. This represents pipeline diversification, creating a separate value-creating program with distinct clinical and commercial potential.
Dual-track development reduces company-level risk by not relying solely on one therapeutic platform. The delirium program operates independently of the antibody platform, providing multiple paths to value creation as both advance through their respective development stages.
Want the Next Biotech Breakthrough in Your Inbox?
Join 20,000+ investors receiving FREE ASX biotech alerts within minutes of release, complete with in-depth analysis. Click the “Free Alerts” button at StockWire X to get market-moving news and expert coverage delivered directly to your inbox before the market reacts.